Form 4: Neogenomics COO Reports Stock Transaction
Insider Transaction (Form 4)
Warren Stone, Pres & Chief Operating Officer of Neogenomics Inc, reported multiple transactions in common stock on October 1, 2026.
Summary
- Option exercise/conversion: acquired 17,562 Common Stock on October 1, 2026; holds 198,640 after (Direct).
- Tax/exercise-price withholding: disposed of 6,911 Common Stock on October 1, 2026; holds 191,729 after (Direct).
- Option exercise/conversion: disposed of 17,562 Restricted Stock Unit on October 1, 2026; holds 17,563 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Warren Stone — Officer (Pres & Chief Operating Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-01 | Option exercise/conversion | Common Stock | 17,562 | — | — | 198,640 |
| 2026-10-01 | Tax/exercise-price withholding | Common Stock | 6,911 | — | — | 191,729 |
| 2026-10-01 | Option exercise/conversion | Restricted Stock Unit | 17,562 | — | — | 17,563 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-01 | Option exercise/conversion (17,562 shares) |
| 2026-10-01 | Tax/exercise-price withholding (6,911 shares) |
| 2026-10-01 | Option exercise/conversion (17,562 shares) |
Keywords
insider transaction, Form 4, NEO, NEOGENOMICS INC, neutral, Warren Stone
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.